Clinical Medicine and Therapeutics最新文献_第6页

pharmacotherapy Update: Risperidone in the Treatment of schizophrenia 药物治疗最新进展:利培酮治疗精神分裂症

Clinical Medicine and Therapeutics Pub Date : 2009-09-07 DOI: 10.4137/CMT.S1123

M. Raja

{"title":"pharmacotherapy Update: Risperidone in the Treatment of schizophrenia","authors":"M. Raja","doi":"10.4137/CMT.S1123","DOIUrl":"https://doi.org/10.4137/CMT.S1123","url":null,"abstract":"The paper is a review of the clinical use of risperidone, an antipsychotic introduced in the treatment of schizophrenia in 1994. Randomized controlled trials, naturalistic studies and extensive clinical experience have definitively shown strong efficacy and effectiveness of risperidone in the treatment of schizophrenia and other psychotic disorders. On the basis of available evidence, no other antipsychotic drug has shown superior clinical effectiveness in the treatment of psychotic disorders, with the significant exception of clozapine. The wide use of risperidone in the last 15 years has confirmed a favorable safety index. Some features of risperidone render it uniquely useful in the management of psychotic disorders, including a very wide range of dosage, availability in liquid and long-term injectable forms. Finally, the drug is currently available in generic form, at lower cost. However, risperidone presents major limitations. A substantial number of patients with psychotic symptoms do not respond to risperidone, whatever its dose. Most of these patients will need clozapine. For some risperidone treated patients, extrapyramidal side effects remain a serious concern. Weight gain, metabolic syndrome, and hyperprolactinemia related side effects are frequent and may be severe, unacceptable, and even dangerous in some patients.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89269050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting 盐酸帕洛诺司琼治疗化疗引起的恶心呕吐

Clinical Medicine and Therapeutics Pub Date : 2009-09-03 DOI: 10.4137/CMT.S2179

Quan-wang Li, J. Roddy, Michael Berger

{"title":"Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting","authors":"Quan-wang Li, J. Roddy, Michael Berger","doi":"10.4137/CMT.S2179","DOIUrl":"https://doi.org/10.4137/CMT.S2179","url":null,"abstract":"Chemotherapy-induced nausea and vomiting (CINV) is among the most unpleasant and stressful aspects of chemotherapy. Poorly controlled nausea and vomiting may have negative impacts on clinical treatment and quality of life. Clinical trials aimed at the prevention of CINV have focused on both acute and delayed phases of CINV. The use of first generation serotonin subtype 3 serotonin (5-HT3) receptor antagonists has significantly improved symptom control in acute CINV. However, they are less effective in controlling delayed CINV. Palonosetron is a second generation 5-HT3 receptor antagonist with high potency, selectivity, prolonged half-life, and a unique allosteric binding mechanism. Previous trials which compared palonosetron to other first generation 5-HT3 antagonists had used the prevention of delayed CINV as a secondary end point. Recent data have demonstrated palonosetron, when used with a corticosteroid, was superior to granisetron in the prevention of delayed CINV as a primary end point. This article will review recently published literature focusing on mechanism of action, metabolism, pharmacokinetics, clinical efficacy, and safety of palonosetron in the treatment of CINV, specifically delayed CINV.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88257409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A Review of Raltegravir and its Use in HIV-1 Infection 雷替格拉韦及其在HIV-1感染中的应用综述

Clinical Medicine and Therapeutics Pub Date : 2009-09-03 DOI: 10.4137/CMT.S1985

C. Boesecke, L. Gelgor

{"title":"A Review of Raltegravir and its Use in HIV-1 Infection","authors":"C. Boesecke, L. Gelgor","doi":"10.4137/CMT.S1985","DOIUrl":"https://doi.org/10.4137/CMT.S1985","url":null,"abstract":"Raltegravir is the first antiretroviral drug in the class of integrase inhibitors approved for the treatment of human immunodeficiency virus type 1 (HIV-1) in combination with other antiretroviral agents in treatment-experienced adults with evidence of ongoing viral replication and resistance to multiple antiretroviral drugs. Since raltegravir has a different mechanism of action to the currently licensed antiretroviral agents, it is a welcome addition in the treatment of HIV-1. Results from clinical studies to date indicate that raltegravir exhibits potent antiviral activity particularly against HIV-1 strains which exhibit resistance to other classes of antiretroviral drugs. It is well tolerated and has a favorable safety profile. Long-term follow-up data on its resistance profile and on potential interactions with other antiretroviral as well as concomitant medications will ultimately define its future role in the treatment of HIV-1 infection. This review briefly describes the mechanism of action of raltegravir and its pharmacokinetic profile, summarizes efficacy and safety data from recent clinical trials and implications for the use in treatment-naive as well as treatment-experienced patients, depicts raltegravir’s emerging resistance profile, and highlights potential drug-drug interactions.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75219873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Re-assessment of the Safety and Efficacy of Interleukin-2 for the Treatment of Renal Cell Carcinoma 白介素-2治疗肾细胞癌安全性和有效性的再评价

Clinical Medicine and Therapeutics Pub Date : 2009-08-31 DOI: 10.4137/CMT.S2037

A. Jarkowski, M. Wong

引用次数: 2

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Rampiril 降低心肌梗死、中风和心血管疾病死亡的风险。重点服用Rampiril

Clinical Medicine and Therapeutics Pub Date : 2009-08-31 DOI: 10.4137/CMT.S2095

M. Khazaei, A. Sharifi, S. Golbidi, I. Laher

引用次数: 0

cardiotoxicity of Oral Methadone as an Analgesic— recommendations for safe Use 口服美沙酮作为镇痛药的心脏毒性——安全使用的建议

Clinical Medicine and Therapeutics Pub Date : 2009-08-31 DOI: 10.4137/CMT.S3041

D. Guay

引用次数: 5

exudative Age-Related Macular Degeneration: current Therapies and potential Treatments 渗出性年龄相关性黄斑变性:目前的治疗方法和潜在的治疗方法

Clinical Medicine and Therapeutics Pub Date : 2009-08-27 DOI: 10.4137/CMT.S2225

P. Quiram, Yahui Song

引用次数: 0

Safety and Efficacy of Doxycycline 多西环素的安全性和有效性

Clinical Medicine and Therapeutics Pub Date : 2009-08-27 DOI: 10.4137/CMT.S2860

P. Leggat

引用次数: 5

Safety and Efficacy of Eplerenone in the Management of Essential Hypertension 依普利酮治疗原发性高血压的安全性和有效性

Clinical Medicine and Therapeutics Pub Date : 2009-08-25 DOI: 10.4137/CMT.S2211

F. McManus, J. Connell

{"title":"Safety and Efficacy of Eplerenone in the Management of Essential Hypertension","authors":"F. McManus, J. Connell","doi":"10.4137/CMT.S2211","DOIUrl":"https://doi.org/10.4137/CMT.S2211","url":null,"abstract":"Suppression of the Renin-Angiotensin-Aldosterone system (RAAS) is an established intervention in the management of cardiovascular disease. Large, randomized controlled trials have provided a sound evidence base for the use of mineralocorticoid receptor antagonists to block the end product of the RAAS in the treatment of heart failure. However, the place for mineralocorticoid blockade in the treatment of hypertension is less well defined and lacking a strong evidence base. The main indication for the use of this strategy in hypertension is as a third line agent in the treatment of refractory hypertension. The most widely used mineralocorticoid receptor antagonist, spironolactone, is associated with dose related sexual side effects, limiting its use in clinical practice. Eplerenone, the selective mineralocorticoid receptor antagonist, is a promising cardiovascular drug licensed for the treatment of heart failure in Europe and heart failure and hypertension in the USA. It effectively blocks the mineralocorticoid receptor without the unpleasant sexual side effect profile of spironolactone. We review the use of eplerenone, a selective mineralocorticoid receptor antagonist in the treatment of hypertension; discuss its mechanism of action, safety profile as well as its current place in therapy.","PeriodicalId":10428,"journal":{"name":"Clinical Medicine and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80953722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences 精神分裂症患者的抗精神病药物治疗:理论背景、临床考虑和患者偏好

Clinical Medicine and Therapeutics Pub Date : 2009-08-17 DOI: 10.4137/CMT.S2175

R. Nielsen, J. Nielsen

引用次数: 9